FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

Macitentan

Drug and asset intelligence for Macitentan with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 2
Stage: Development stage unavailable

Sponsor company

Teva →

Recent signals(2)

RegulatoryJuly 19, 2026

FDA Accepts Supplemental Application for Macitentan by Seasons Biotech

The FDA has accepted a supplemental application for Macitentan submitted by Seasons Biotech.

StrategyJune 23, 2026

FDA Grants Approval for Macitentan ANDA211187 by Teva Pharmaceuticals

Teva Pharmaceuticals has received approval for its Abbreviated New Drug Application (ANDA211187) for Macitentan.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

— Macitentan

July 19, 2026 · N/A

Topline Data

Teva — Macitentan

June 23, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Cardiology →

Cardiology · Pulmonary Arterial Hypertension →

Pulmonary Arterial Hypertension →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.